Table 2.
The characteristics of patients who developed biochemical, clinical failure or death from prostate cancer
| Biochemical failure | Clinical failure | Prostate cancer death | |
|---|---|---|---|
| Number of patients | 97 | 45 | 13 |
| Age (years) | |||
| Median | 69 | 68 | 67 |
| IQR | 63–73 | 61–71 | 62–75 |
| Clinical T stage, n (%) | |||
| T1c | 8 (8.2) | 2 (4.4) | 1 (7.7) |
| T2a | 5 (5.2) | 2 (4.4) | 0 (0) |
| T2b | 3 (3.1) | 1 (2.2) | 0 (0) |
| T2c | 5 (5.2) | 4 (8.9) | 0 (0) |
| T3a | 45 (46.4) | 20 (44.5) | 6 (46.1) |
| T3b | 27 (27.8) | 13 (28.9) | 4 (30.8) |
| T4 | 4 (4.1) | 3 (6.7) | 2 (15.4) |
| iPSA (ng/mL) | |||
| Median | 31.2 | 24.7 | 27.1 |
| IQR | 18.5–49.2 | 14.6–38.1 | 13.4–33.0 |
| Gleason score, n (%) | |||
| 6 | 3 (3.1) | 0 (0) | 0 (0) |
| 7 | 35 (36.1) | 14 (31.1) | 4 (30.8) |
| 8 | 32 (33.0) | 16 (35.5) | 5 (38.4) |
| 9 | 24 (24.7) | 12 (26.7) | 3 (23.1) |
| 10 | 3 (3.1) | 3 (6.7) | 1 (7.7) |
| NCCN risk classification, n (%) | |||
| High-risk | 49 (50.5) | 20 (44.4) | 5 (38.5) |
| Very high-risk | 48 (49.5) | 25 (55.6) | 8 (61.5) |